Application
Fig1: Western blot analysis of eIF2α phosphorylation in untreated (A, C) and lambda protein phosphatase treated (B, D) HEK293 whole cell lysates. Antibodies tested include p-eIF2α (Ser 52)(A, B) and eIF2α(C, D).Application
Fig2： Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.| Product Name | Phospho-eIF-2a (Ser 52) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | EIF 2 alpha antibody EIF 2 antibody EIF 2A antibody EIF 2alpha antibody eIF-2-alpha antibody eIF-2A antibody EIF-2alpha antibody EIF2 alpha antibody EIF2 antibody EIF2A antibody EIF2S1 antibody Eukaryotic translation initiation factor 2 subunit 1 alpha 35kDa antibody Eukaryotic translation initiation factor 2 subunit 1 alpha antibody Eukaryotic translation initiation factor 2 subunit 1 antibody Eukaryotic translation initiation factor 2 subunit alpha antibody IF2A_HUMAN antibody |
| Product description | The initiation of protein synthesis in eukaryotic cells is regulated by interactions between protein initiation factors and RNA molecules. The eukaryotic initiation complex is composed of three subunits, designated eIF2, eIF2 and eIF2 (eukaryotic translation initiation factor 2 , and , respectively), all of which work in concert to form a ternary complex with GTP and tRNA in the early stages of protein synthesis. eIF2, also known as EIF2S1 or EIF2, is a 315 amino acid subunit of the eukaryotic initiation complex that functions to bind tRNA to the 40S ribosomal subunit (in a GTP-dependent manner), thereby initiating translation. In addition, the phosphorylation state of eIF2 controls the rate of tRNA translation. When eIF2 is not phosphorylated, translation occurs at a normal rate. However, upon phosphorylation by one of several kinases, eIF2 is stabilized, thus preventing the GDP/GTP exchange reaction and slowing translation. |
| Immunogen | A short amino acid sequence containing phosphorylated Ser 52 of eIF2α of human origin. |
| Modification | p-Ser 52 |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBIPIFIHC-P |
| WB:1:100-1:1,000 IP:1-2 μg per 100-500 μg of total protein (1 ml of cell lysate) IF:1:50-1:500 IHC:1:50-1:500 |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Alternative Names | EIF 2 alpha antibody EIF 2 antibody EIF 2A antibody EIF 2alpha antibody eIF-2-alpha antibody eIF-2A antibody EIF-2alpha antibody EIF2 alpha antibody EIF2 antibody EIF2A antibody EIF2S1 antibody Eukaryotic translation initiation factor 2 subunit 1 alpha 35kDa antibody Eukaryotic translation initiation factor 2 subunit 1 alpha antibody Eukaryotic translation initiation factor 2 subunit 1 antibody Eukaryotic translation initiation factor 2 subunit alpha antibody IF2A_HUMAN antibody |
|---|---|
| Molecular Weight(MW) | 36 kDa |
| Cellular Localization | Cytoplasmic granule |
| SwissProt ID | P05198 |
|---|
Application
Fig1: Western blot analysis of eIF2α phosphorylation in untreated (A, C) and lambda protein phosphatase treated (B, D) HEK293 whole cell lysates. Antibodies tested include p-eIF2α (Ser 52)(A, B) and eIF2α(C, D).
Application
Fig2： Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.| Positive Control | HEK293, human breast carcinoma tissue. |
|---|---|
| Application Notes | WB:1:100-1:1,000 IP:1-2 μg per 100-500 μg of total protein (1 ml of cell lysate) IF:1:50-1:500 IHC:1:50-1:500 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
